TIDES Asia - Leaders In

24-26 February, 2026
Grand Nikko Tokyo Daiba, Tokyo

Welcome to TIDES Asia 2026

Connect with Leaders in Oligonucleotide & Peptide Therapeutics

This is where the future comes to life, and these top companies are leading the way with cutting-edge technology, groundbreaking ideas, and bold visions. Whether you’re looking for fresh inspiration, potential partnerships, or the latest advancements, this list is your connection to the industry’s top innovators. Visit their booths, explore their tech, and book meetings to connect with the leaders shaping what’s next.

Find where our sponsors are located on the show floor!

Download Floor Map

AmbioPharm, a global peptide CDMO, was founded in 2005 and is headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient peptide manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at small to very large scales. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) and peptide APIs under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA with excellent outcomes.

Schedule a Meeting

Website

Thursday, 26 February 2026, 12:00pm - 12:30pm

Greener, Smarter Peptide Manufacturing: Advancing Sustainability and Quality

Discover how Cyclover amine tag-assisted liquid-phase peptide synthesis (LPPS) achieves higher yields, greener purity and lower carbon footprint compared to solid-phase peptide synthesis (SPPS). By using greener solvents, reducing reagent consumption, and shortening production cycles, this method helps pharmaceutical companies meet sustainability goals and accelerate delivery of consistently high-quality therapeutic peptides to patients.

Speaker:

Anubrato Aich
Senior Project Manager at AmbioPharm

Cytiva and Pall Life Sciences have come together to deliver the breadth, depth, and scale researchers and biopharma need to advance future therapeutics – from discovery to delivery. Together, as Cytiva, we supply the tools and support our customers need to work better, faster and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com for more.

Cytiva is proud to be part of Danaher.

Danaher is a global science and technology leader. Together we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology to improve human health.

Schedule a Meeting

Visit Our Booth: 11

Website

Wednesday, 25 February 2026, 9:45am - 10:15am

Redefining Standards: Empowering Sustainable Synthesis

You’re the expert in your molecule and have the ambition to advance healthcare and treat patients. RNA-based oligonucleotides are an important part of future treatments. At Cytiva, we’ve been all things oligo for over four decades, and our prior knowledge and process experience could make a difference for your in-house R&D, process development, and scale-up. In this presentation, we’ll share some of our key learnings that can help you optimize resource use and future RNA synthesis.

Speaker:

Dr. Ganesh Nawale, PhD
Senior Scientist at Cytiva

Simplifying Progress

We are living in the bio-century. Global medical knowledge is expanding at a rapid pace. But despite huge breakthroughs, many diseases, such as cancer, rheumatism or Alzheimer’s, are still not curable.

Sartorius is part of the solution. We help to ensure that new scientific discoveries can be translated more quickly into effective patient care. With technologies, platforms and partnerships for a common goal: better health for more people.

Schedule a Meeting

Visit Our Booth: 42

Website

Thursday, 26 February 2026, 11:00am - 11:30am

Enhancing GLP-1 Manufacturing: Addressing TFF Challenges

The Tangential Flow Filtration (TFF) steps in the GLP-1 process encounter distinct challenges due to specific requirements for membrane chemistries, flux, retention profiles, and chemical compatibility. Hydrosart®, with its unique chemistry and construction, stands out as the premier TFF membrane for GLP-1 processes. It ensures optimal outcomes by enhancing key process parameters during the TFF steps, making it the preferred choice for achieving superior results.

Speaker:

Dr. Fabian Jakob
Manager of Tangential Flow Filtration Materials at Sartorius

Hybio Pharmaceutical Co., Ltd., a national high-tech enterprise, specialized in R&D, production and marketing of peptide drugs, with a focus on peptide drugs and Oligonucleotide Drug. Listed on the Shenzhen Stock Exchange in 2011 (stock code: 300199), it is among China’s earliest listed peptide drug companies.
Boasting national-level platforms like the National and Local Joint Engineering Laboratory for Peptide Drugs, it has undertaken multiple national projects and won honors including the Second Prize of National Technological Invention Award, China Patent Excellence Award, and entitled as National Intellectual Property Demonstration Enterprise.

GMP certified by China NMPA, US FDA, EU EMA, Brazil ANVISA, Australia TGA, Indonesian BPOM, South Korea MFDS, etc., it has built a vertical integrated industrial chain covering API、finished dosage and marketing, securing supply chain from raw materials to drugs. Adhering to the vision of continuous innovation to lead the peptide industry, Hybio takes protecting life and health as its eternal mission.

Schedule a Meeting

Visit Our Booth: 12

Website

Wednesday, 25 February 2026, 10:35am - 10:50am

From Molecule to Market: An Integrated CRDMO Approach for Peptides

This presentation explores key challenges encountered across peptide discovery, development, scale-up and manufacturing and highlights the importance of an integrated CRDMO model. Using a molecule-to-market perspective, the talk discusses how close alignment across early discovery, process development, GMP manufacturing, and life cycle management can reduce technical risks, improve efficiency, and support global peptide programs from early development through commercial supply.